HALIX
HALIX is a Netherlands-based biologics CDMO providing end-to-end GMP manufacturing of viral vectors, vaccines, and recombinant proteins for biotech startups and large pharma from its 6,700 m² Leiden Bio Science Park facility.
- Company typePrivate
- Founded2012
- HeadquartersLeiden, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingServices
What HALIX does
HALIX is a Netherlands-based biopharmaceutical contract development and manufacturing organization (CDMO) founded in 2012 as a spin-off of HAL Allergy Group, wholly owned by the German Droege Group AG conglomerate. The company provides end-to-end GMP manufacturing services for biologics across three integrated service lines: viral vector and vaccine manufacturing, recombinant protein and antibody manufacturing, and aseptic fill/finish with lyophilization, serving both small biotech startups and large pharmaceutical companies across preclinical through commercial stages. Its technology platform is built on mammalian expression systems (HEK293, CHO, PER.C6, HeLa, VERO, SF9) with scalable single-use bioreactor capacity up to 1,000 L, supported by 10 EU GMP-grade clean rooms, BSL2 containment with BSL3 upgrade capability, and a 6,700 m² purpose-built facility at Leiden Bio Science Park operational since 2019.
The company's revenue model is project-based contract manufacturing with custom pricing per engagement, driven by direct enterprise sales managed by specialized Business Development directors segmented by therapeutic modality (viral vectors, recombinant proteins, fill/finish). HALIX gained significant commercial credibility through its role in the Oxford/AstraZeneca consortium, manufacturing 80+ million doses of the AZD1222 COVID-19 vaccine following EMA approval in March 2021. In April 2024, HALIX launched the HALiXPEDITE platform to bridge late-stage R&D and GMP manufacturing with an embedded BioHub ecosystem, followed by a December 2024 strategic partnership with Rocketvax for VIRUFLEX pandemic preparedness vaccines. The company employs 70+ staff (per its own description) and reports a 90% customer retention rate across 75+ clients.
HALIX firmographics
Firmographics- Name
- HALIX
- Legal name
- HALIX B.V.
- Website
- https://halix.nl
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- HALIX is a Netherlands-based biologics CDMO providing end-to-end GMP manufacturing of viral vectors, vaccines, and recombinant proteins for biotech startups and large pharma from its 6,700 m² Leiden Bio Science Park facility.
- Ownership category
- akta.pro rank
HALIX industry classification
Industry- Product category
- Biopharmaceutical Contract Development and Manufacturing (CDMO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)
- akta.pro secondary industries
- Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)
Keywords
Where HALIX is headquartered
LocationHeadquarters
- HQ city
- Leiden
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
HALIX business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
Revenue model
- Contract Development and Manufacturing (CDMO) Services: HALIX generates revenue through contract manufacturing agreements for the development and GMP manufacturing of biologics including viral vectors, vaccines, and recombinant proteins. Services span from preclinical to commercial scale, including drug substance and drug product manufacturing, fill-finish, and lyophilization. Revenue is project-based, driven by contracts with pharma and biotech companies for clinical trial material and commercial supply.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
HALIX product offering
Product offeringCore offering
HALIX is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end GMP manufacturing services for viral vectors, vaccines, and recombinant proteins. Services span preclinical to commercial scale, including process development, drug substance and drug product manufacturing, aseptic fill-finish, and lyophilization. The company operates from a 6,700 m² state-of-the-art GMP facility at Leiden Bio Science Park with single-use bioreactor capacity up to 1,000 L and BSL2/BSL3-capable cleanroom infrastructure.
Product overview
HALIX is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services for biologics manufacturing. The core portfolio consists of three integrated service lines: Viral Vector Manufacturing (for oncolytic viruses, gene therapies, and vaccines), Recombinant Protein Manufacturing (for mAbs, bispecific antibodies, and therapeutic proteins), and Aseptic Fill & Finish with Lyophilization. These core products are supported by Development Services for process scale-up, Cell Bank Production, Quality Control/Testing, and Labeling/Packaging. The HALiXPEDITE Platform serves as a unified interface providing integrated expertise from cell line development through GMP manufacturing, complemented by the BioHub ecosystem connecting researchers to IP, AI/ML, and CMC expertise. The company operates mammalian expression systems (CHO, HEK293, PER.C6, HeLa) with capacities up to 1,000 L SUB scale from preclinical through commercial scale.
Differentiator
Problem solved
Functional benefit
Brands
- HALiXPEDITE: A platform bridging late-stage research and GMP manufacturing for biologics therapy development, providing integrated expertise and infrastructure from cell line development to GMP production.
Products and services
- Viral Vector Manufacturing End-to-end GMP manufacturing of viral vectors for oncolytic immunotherapies, cell and gene therapies, and therapeutic/prophylactic vaccines using mammalian expression systems. Supports adenovirus, lentivirus, AAV, and other viral vectors from adherent and suspension cell lines up to 1,000 L SUB scale, intended for pharmaceutical and biotechnology companies from clinical through commercial stage.
- Recombinant Protein Manufacturing GMP manufacturing of recombinant proteins and antibodies including monoclonal antibodies, bispecific antibodies, biosimilars, and therapeutic proteins using mammalian expression systems (CHO, HEK293, PER.C6, HeLa cell lines) up to 1,000 L single-use bioreactor scale, serving pharmaceutical and biotechnology companies from clinical through commercial stages.
- Aseptic Fill and Finish with Lyophilization GMP-certified aseptic fill and finish services for clinical and commercial scale drug products, including lyophilization cycle development (0.5 m² pilot to 5.0 m² commercial freeze dryer), automated filling line under Grade A in Grade B cleanroom, small and large scale aseptic filling up to 20,000 vials per batch, and BSL2-capable small scale filling for pharmaceutical and biotechnology customers.
- Development Services Process development and scale-up services spanning from small scale production to 1,000 L industrial scale, including lyophilization cycle development, analytical development, and QbD/DoE-based process optimization for viral vectors, recombinant proteins, and vaccines, serving pharmaceutical and biotechnology companies from preclinical through clinical stages.
- HALiXPEDITE Platform A platform bridging late-stage research and GMP manufacturing for biologics therapy development, providing integrated expertise and infrastructure from cell line development to GMP production, with access to a BioHub connecting researchers, drug developers, and industry partners to IP, ML/AI, and CMC management through a single point of contact. Targeted at small biotech startups and pharmaceutical companies seeking accelerated biologics development.
Quantifiable outcome
- 3 billion+ doses of ChAdOx1 COVID-19 vaccine supplied globally through consortium, saving 6 million+ lives
- +5 more outcomes
Companies that use HALIX
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
HALIX technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
HALIX partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, flagship and minor.
- Rocketvax AGcoreHALIX was selected as a strategic CDMO partner for Rocketvax's VIRUFLEX endemic readiness platform and next-generation nasal COVID-19 vaccine. HALIX provides GMP-grade manufacturing, viral vector expertise, and scalable infrastructure. Rocketvax's nasal vaccine uses reverse genetic engineering for live-attenuated SARS-CoV-2, offering nasal immunity, broad protein recognition, transmission prevention, and room-temperature stability.
- U.S. National Institutes of Health (NIH)flagshipRocketvax signed a letter of intent with NIH for clinical development and global access of its nasal COVID-19 vaccine. As HALIX's partner for VIRUFLEX manufacturing, HALIX is indirectly involved in this government collaboration.
- University of OxfordflagshipHALIX joined the University of Oxford's consortium as an early partner in Q1 2020 to scale up and optimize production of the ChAdOx1 nCoV-19 COVID-19 vaccine. HALIX focused on scaling up and optimizing the production process and producing clinical trial material. The consortium ultimately supplied over 3 billion doses globally. HALIX was named a finalist for the 2024 MacRobert Award alongside Oxford and AstraZeneca.
- NovalGencoreStrategic partnership for GMP manufacture of clinical trial materials. HALIX produced NVG-111 bispecific antibody from drug substance to drug product in under 7 months. NovalGen's manufacturing process used transient transfection to accelerate timelines and reduce costs.
- AstraZenecaflagshipHALIX signed an agreement with AstraZeneca for large-scale commercial drug substance manufacture of AZD1222 COVID-19 vaccine. HALIX expanded with two additional viral vector production lines to meet demand. The facility was EMA-approved in March 2021. HALIX produced commercial batches covering over 80 million vaccine doses.
- University of Oxford Jenner InstituteflagshipHALIX joined the consortium under University of Oxford's guidance to provide GMP manufacturing services for ChAdOx1 nCoV-19 vaccine. HALIX utilized its new GMP facility with 1,000 L SUB capacity and viral vector expertise to transfer an industrial-scale drug substance process and manufacture clinical trial material.
- Vaccine Manufacturing and Innovation Centre (VMIC)minorPart of the University of Oxford ChAdOx1 coronavirus vaccine alliance, alongside the Clinical Biomanufacturing Facility, VMIC, Pall Biotech, and Cobra Biologics. Contributed to viral vector manufacturing and regulatory compliance.
- Cobra BiologicsminorPart of the University of Oxford ChAdOx1 coronavirus vaccine alliance for viral vector manufacturing and regulatory compliance.
- Leiden UniversitycoreHALIX signed an agreement with Leiden University for a plot of land at the Leiden Bio Science Park. This was the kick-off for the design and construction of HALIX's GMP facility. The Leiden Bio Science Park is the largest science cluster in the Netherlands, bringing together Leiden University, LUMC, and approximately 150 companies.
Scale indicators7 records
Recent moves10 records
Expansion highlights5 records
HALIX competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: World's largest CDMO with extensive biologics, cell & gene therapy, and viral vector capacity across mammalian and microbial platforms. Sets the global benchmark for scale and pricing against which HALIX must position as a more agile European alternative.
- Catalent (Novo Holdings): Global CDMO offering biologics, viral vectors, fill-finish, and cell therapy services at scale; recently acquired by Novo Holdings. Competes for the same pharma and biotech contracts as HALIX across viral vector and fill-finish.
- Thermo Fisher Scientific (Patheon CDMO): Diversified CDMO through Patheon providing biologics development, viral vector manufacturing, and fill-finish at global scale. Represents the largest integrated competitor to HALIX across all of HALIX's core services.
- Boehringer Ingelheim BioXcellence: Large biopharmaceutical CDMO offering mammalian- and microbial-based biologics, viral vectors, and aseptic fill-finish services. Strong European competitor that competes with HALIX for both regional biotech and large pharma contracts.
Direct peers
- Cobra Biologics (Charles River): Viral vector and plasmid DNA CDMO (acquired by Charles River); participated alongside HALIX in the University of Oxford ChAdOx1 manufacturing consortium in 2020. Direct peer in viral vector manufacturing.
- Vibalogics: Pure-play viral vector CDMO for vaccines, gene therapies, and oncolytic viruses, with BSL2/BSL3 capabilities and AAV/lentiviral expertise. Most direct competitor to HALIX's viral vector manufacturing focus.
- Polyplus ( transfection / process solutions): Provider of viral vector manufacturing solutions and CDMO services including process development and GMP manufacturing; overlaps with HALIX's transient transfection and viral vector capabilities.
- Wacker Biotech: German CDMO for microbial and mammalian biologics including live biotherapeutics and viral vectors. Comparable mid-sized European CDMO focused on GMP contract manufacturing for biologics.
- Rentschler Biologics: Privately held German CDMO for mammalian cell-culture biologics, recombinant proteins, and viral vectors. Closely comparable mid-sized European CDMO serving both small biotech and large pharma with similar mammalian expression focus.
- AGC Biologics: Global CDMO specializing in mammalian- and microbial-based biologics, viral vectors (AAV, lentiviral), and cell therapy manufacturing. Direct competitor across HALIX's viral vector and recombinant protein service lines, with similar position in clinical and commercial-scale supply.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
HALIX social profiles
Digital presenceHALIX compliance and trust
Trust signalCompliance5 records
HALIX financial estimates
Financial estimateRevenue estimate
Valuation estimate
HALIX leadership team
Management profileNumber of profiles
Profiles8 records
HALIX funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HALIX M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HALIX
What does HALIX do?
HALIX is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end GMP manufacturing services for viral vectors, vaccines, and recombinant proteins. Services span preclinical to commercial scale, including process development, drug substance and drug product manufacturing, aseptic fill-finish, and lyophilization. The company operates from a 6,700 m² state-of-the-art GMP facility at Leiden Bio Science Park with single-use bioreactor capacity up to 1,000 L and BSL2/BSL3-capable cleanroom infrastructure.
Is HALIX a public or private company?
HALIX is a private company. It is classified as corporate owned and is currently operating.
When was HALIX founded?
HALIX was founded in 2012. It employs 11 to 50 people.
Where is HALIX based?
HALIX is headquartered in Leiden, Netherlands, in the Europe region.
How does HALIX make money?
One revenue line is on record: contract Development and Manufacturing (CDMO) Services.
Who are HALIX's main competitors?
Broad incumbents on record are Lonza Group, Catalent (Novo Holdings), Thermo Fisher Scientific (Patheon CDMO) and Boehringer Ingelheim BioXcellence. Direct peers are Cobra Biologics (Charles River), Vibalogics, Polyplus ( transfection / process solutions), Wacker Biotech, Rentschler Biologics and AGC Biologics.
Does HALIX have an API?
No public API is recorded for HALIX.
What industry is HALIX in?
HALIX's product category is Biopharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO, with a secondary code of HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 325412 and its SIC code is 8731.